Cardiovascular frailty emerges as distinct phenotype linking heart health and aging

Doctors have long known that frailty and heart disease travel together in aging bodies, but the mechanisms linking them remain poorly understood. A new narrative review published in the Journal of Human Hypertension proposes that cardiovascular frailty should be recognized as its own distinct condition—a phenotype that weaves together blood pressure dysregulation, vascular stiffening, chronic inflammation, and the physical decline characteristic of frailty itself. The authors argue that if researchers can develop and validate a cardiovascular frailty index, it could transform how clinicians detect vulnerability early and tailor treatment to individual patients. But the work remains preliminary; longitudinal studies will be needed before such an index moves from theory into practice.

The backdrop is straightforward: as healthcare systems improve and people live longer, the number of frail older adults worldwide has grown substantially. Frailty itself is defined as an age-related state of reduced physiological reserves and heightened vulnerability—the condition that makes an older person susceptible to serious health decline even from minor stressors. Clinicians currently assess frailty using two main frameworks: the Rockwood Clinical Frailty Scale, which measures cumulative deficits, and Fried's phenotype model, which focuses on physical decline. Yet neither fully captures the biological underpinnings of frailty, nor do they adequately explore how cardiovascular, cognitive, and psychosocial factors interweave with it. Newer models have begun to address vascular, cognitive, and social frailty, but cardiovascular frailty has remained largely unexplored territory.

The stakes are substantial. Research has established that frailty and cardiovascular disease exist in a bidirectional relationship: people with pre-frailty or frailty face a 70 percent higher risk of cardiovascular disease overall, while those with frailty carry nearly three times the risk of cardiovascular death compared to their non-frail peers. Scientists have hypothesized that oxidative stress, inflammation, DNA damage, cardiac remodeling, hormonal dysregulation, cellular senescence, and epigenetic changes may drive this connection. Understanding these mechanisms is essential if clinicians are to intervene effectively.

One key pathway involves what researchers call oxi-inflammaging—the pairing of oxidative stress and chronic inflammation that accumulates with age. Older adults with frailty consistently show higher levels of both oxidative stress and inflammatory markers than those without frailty. Poor nutrition, sedentary living, genetic predisposition, and age-related diseases all contribute to free radical production and tissue damage. Studies have identified specific biomarkers of inflammation and oxidative stress that correlate with increased frailty risk, and people with frailty tend to have lower antioxidant levels alongside elevated oxidative stress markers. Much of this evidence is cross-sectional, meaning directionality and causation remain uncertain, but the pattern suggests oxi-inflammaging plays a role in frailty's pathophysiology. Notably, oxi-inflammaging also drives cardiovascular disease, and lifestyle factors that increase cardiovascular risk—poor diet, inactivity—also fuel oxi-inflammaging, creating a reinforcing cycle.

Vascular aging compounds the problem. As blood vessels change structurally and functionally over time, they become stiffer, altering blood flow and straining the cardiovascular system. Arterial stiffness is independently linked to isolated systolic hypertension in older adults and has been consistently associated with frailty and disability in both cross-sectional and longitudinal studies. This suggests that interventions reducing arterial stiffness or slowing vascular aging might lower hypertension and cardiovascular risk while potentially improving frailty outcomes.

Blood pressure regulation itself becomes complicated in frail older adults. Hypertension, isolated systolic hypertension, orthostatic hypotension (sudden drops in blood pressure upon standing), and white coat hypertension (elevated readings in clinical settings) all occur more frequently in this population. The interplay among these conditions stems from blood pressure variability, autonomic nervous system dysfunction, endothelial damage, and vascular stiffness. Conditions like diabetes, atrial fibrillation, chronic kidney disease, stroke, and heart failure amplify this complexity. Vascular inflammation and oxidative stress can damage the endothelium, impairing the vessels' ability to expand and disrupting baroreceptor function—the system that senses and adjusts blood pressure. Vascular stiffness further reduces baroreceptor sensitivity, contributing to orthostatic hypotension. These mechanisms interconnect and are compounded by both aging and frailty itself.

Yet treating hypertension in frail older adults remains clinically uncertain. An analysis of the HYVET trial found that frailty did not appear to blunt the benefits of blood pressure-lowering medications in adults over 80. Paradoxically, observational evidence suggests that lower blood pressure correlates with excess mortality in frail older adults, while hypertension generally does not predict higher mortality in those 85 and older, regardless of frailty status. International hypertension guidelines from the European Society of Hypertension and the National Institute for Health and Care Excellence now recommend clinical judgment and careful risk-benefit assessment in frail older adults with multiple conditions—a reflection of how little evidence exists for this population, since frail individuals have historically been excluded or underrepresented in hypertension trials.

The authors conclude that the field needs to develop and test a cardiovascular frailty index that integrates blood pressure regulation, vascular aging, oxi-inflammaging biomarkers, and self-reported frailty deficits. Such a tool could offer an objective means of detecting vulnerability early and guiding personalized management. But before it enters clinical practice, longitudinal studies must confirm the proposed connections and validate the index itself. The work ahead is substantial, but the potential payoff—earlier detection and more tailored care for a growing population of vulnerable older adults—makes it worth pursuing.